



Company Overview

Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the world, have improved outcomes for more than ten million patients globally by reducing infection, itch, pain, scarring and harmful inflammatory responses. Sonoma's headquarters are in Petaluma, California, with manufacturing operations in both the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.

Sonoma Pharmaceuticals Announces 1-for-9 Reverse Split of Outstanding Common Stock

Jun 19 2019, 4:05 PM EDT

Sonoma Pharmaceuticals Sells Animal Health Rights in Asia and Europe for \$2.7 million

May 21 2019, 4:05 PM EDT

Sonoma Pharmaceuticals Announces Substantial Cost-Cutting Measures

Mar 12 2019, 6:30 PM EDT

Stock Overview

Symbol	SNOA
Exchange	Nasdaq
Market Cap	10.51m
Last Price	\$7.90
52-Week	\$5.7591 - \$25.200001

06/26/2019 03:59 PM EDT

Investor Relations

T: 707-559-7380
ir@sonomapharma.com

Management Team

Bubba Sandford

CEO/CFO

Bruce Thornton

Executive Vice President

Robert Northey Ph.D

Director of Research and Development

Sonoma Pharmaceuticals, Inc.

1129 North McDowell Blvd.
Petaluma, CA 94954

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.